Mo1338 Is Focal Active Colitis a New Miscellany of Inflammatory Bowel Disease? And Is There a Role for 5 ASA in the Management of FAC?

Banaag, Mareshah Jaira M.; Daulat, E; Mediodia, L; Fernandes, Sónia; Dajani, Asad Izziddin; Abu-Hammour, A; Aljabiri, Mazin R.

doi:10.1016/s0016-5085(13)62371-9

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Banaag et al in their multicenter retrospective study have shown that there are approximately 25% of patients presenting with diarrhea, abdominal pain and IBS with the histological finding of FAC without a definitive diagnosis. More than 50% of patients who had diarrhoea had FAC, and of these 44% responded to 5-aminosalicylic acid (5ASA), evident by resolution of symptoms within two to six weeks [16].…”

Section: Discussionmentioning

confidence: 99%

Focal Active Colitis Presented With Chronic Diarrhea

Mandzhieva

Taylor

Zafar

et al. 2020

Cureus

View full text Add to dashboard Cite

There are various etiologies of colonic injury and inflammation. The most commonly described colitides in clinical practice are associated with infection, inflammatory bowel disease, ischemia, radiation and medications. The colonic wall has a limited set of responses to different types of injury; therefore, there is overlap between many of these disorders. Focal active colitis is characterized by isolated neutrophilic cryptitis with the background mucosa displaying normal crypt architecture. This inflammatory pattern can be easily unnoticed by pathologists because on low-power examination the mucosa may have almost normal appearance. General practitioners also may not be familiar with this term, underlying etiologies, associated risk factors, course, available therapies and follow up. We present a case of an 82-year-old female with chronic diarrhea and weight loss. She had a negative infectious workup and normal radiology series. She subsequently underwent endoscopic evaluation in lieu of persistent and debilitating symptoms which revealed nonspecific macroscopic findings with pathology noting focal active colitis. She was empirically treated with a 14-day course of Xifaxan and responded well to management with almost complete resolution of her symptoms and no recurrence on six-month follow-up.

show abstract

Section: Discussionmentioning

confidence: 99%